Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma
- PMID: 8843965
Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma
Abstract
Reactive oxygen species and other free radicals are known to be the mediators of phenotypic and genotypic changes that lead from mutation to neoplasia. The imbalance in tumor cell antioxidant defense mechanism can influence also the sensitivity to cytoreductive therapy. In erythrocytes it can result to hemolysis which is one of the pathogenetic mechanisms of anemia in cancer patients. Parameters of lipid peroxidation (malondialdehyde-MDA) and antioxidant enzymes here represented by superoxide dismutase (SOD) and glutathione peroxidase (GPx) in multiple myeloma (MM) have been investigated. Nine patients of various clinical stages and activities of the disease were studied. Significantly higher concentrations of total MDA in plasma (1.20 +/- 0.24 mumol/l vs. 0.64 +/- 0.22 mumol/l, p < 0.0001) as well as in erythrocytes (2.72 +/- 0.81 mumol/l vs. 1.03 +/- 0.44 mumol/l, p < 0.0001) were found comparing to the control group. The levels of free MDA in plasma (0.31 +/- 0.09 mumol/l vs. 0.49 +/- 0.17 mumol/l, p < 0.05) and in erythrocytes (0.29 +/- 0.20 mumol/l vs. 0.59 +/- 0.22 mumol/l, p < 0.001) were decreased in myeloma patients. Significantly lower activities of GPx (19.17 +/- 4.07 U/g Hb vs. 23.26 +/- 3.61 U/g Hb, p < 0.05) and SOD (1882.46 +/- 181.73 U/g Hb vs. 2347.13 +/- 502.51 U/g Hb, p < 0.05) in erythrocytes were found. We did not observe evident relationship between the concentration of MDA or the activities of SOD and GPx and either the stage of the disease, or the level and the type of paraprotein. These results propose possible role of free radicals with reduced antioxidant activities of SOD and GPx in multiple myeloma.
Similar articles
-
Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.J Med Assoc Thai. 2010 Jun;93(6):682-93. J Med Assoc Thai. 2010. PMID: 20572373
-
Tumour necrosis factor alpha, lipid peroxidation and NO* are increased and associated with decreased free-radical scavenging enzymes in patients with Weill-Marchesani syndrome.Mediators Inflamm. 2004 Jun;13(3):165-70. doi: 10.1080/09511920410001713547. Mediators Inflamm. 2004. PMID: 15223607 Free PMC article.
-
Physical activity, fitness and integrated antioxidant system in healthy active elderly women.Int J Sports Med. 1998 Oct;19(7):462-7. doi: 10.1055/s-2007-971945. Int J Sports Med. 1998. PMID: 9839842 Review.
-
[Lipid peroxidation and activity of antioxidative enzymes in patients with multiple myeloma].Cas Lek Cesk. 1996 Jan 4;135(1):14-7. Cas Lek Cesk. 1996. PMID: 8599825 Czech.
-
[Membrane phospholipid peroxidation in renal insufficiency and chronic hemodialysis].Nephrologie. 1991;12(1):4-7. Nephrologie. 1991. PMID: 2034320 Review. French.
Cited by
-
Multiple Myeloma from the Perspective of Pro- and Anti-Oxidative Parameters: Potential for Diagnostic and/or Follow-Up Purposes?J Pers Med. 2024 Feb 20;14(3):221. doi: 10.3390/jpm14030221. J Pers Med. 2024. PMID: 38540964 Free PMC article.
-
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.Cell Mol Life Sci. 2021 Apr;78(8):3883-3906. doi: 10.1007/s00018-021-03756-3. Epub 2021 Feb 18. Cell Mol Life Sci. 2021. PMID: 33599798 Free PMC article. Review.
-
Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies.Antioxidants (Basel). 2020 Dec 1;9(12):1212. doi: 10.3390/antiox9121212. Antioxidants (Basel). 2020. PMID: 33271863 Free PMC article. Review.
-
Assessment of serum thiol/disulfide homeostasis in multiple myeloma patients by a new method.Redox Rep. 2017 Nov;22(6):246-251. doi: 10.1080/13510002.2016.1180100. Epub 2016 May 19. Redox Rep. 2017. PMID: 27198712 Free PMC article.
-
Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma.Redox Rep. 2016 Sep;21(5):204-8. doi: 10.1179/1351000215Y.0000000034. Epub 2016 Feb 26. Redox Rep. 2016. PMID: 26218756 Free PMC article.